FDA = A panel of experts from the US Food and Drug Administration will discuss the future of the new coronavirus vaccine and unify the composition of the two vaccines so far in order to get more people vaccinated. unanimously recommended.
On the 26th, the FDA held a committee of external experts to discuss how to proceed with vaccination and development of the new corona vaccine.
Regarding one of the agenda items, the component composition of the vaccine, currently there are "monovalent" corresponding to conventional strains and "bivalent" corresponding to Omicron strains, and it depends on whether it is the first or booster vaccination. .
Regarding this, experts commented one after another that ``simplification will lead to vaccination of more people,'' and they unanimously recommended that the component composition of the vaccine should be unified regardless of the number of times in the future.
On the other hand, there are also discussions on the idea of setting the number of vaccinations to once a year, in principle, and twice a year for young children and the elderly, and to decide at least once a year which vaccines will be developed for which mutants. Although it was exchanged, experts said, "I want to verify more data about children" and "It is important to make vaccines compatible with the latest mutations regardless of the number of times." issued and no conclusions have been reached.
In response to this opinion, the FDA will further consider how to proceed with vaccine development and inoculation in the future.